This paper is a guide to program directors, C-suite executives and other key decision-makers involved in developing and commercialising biopharmaceutical products. It provides critical insights and considerations for selecting the most suitable expression system for manufacturing a particular biologic.
When a new biopharmaceutical product requires bioprocess development for its manufacture or an existing manufacturing system is being upgraded to provide a new or improved supply, there are two immediate considerations:
- What is the best expression system for manufacturing the product?
- To what extent is the biomanufacturing process technically and commercially competitive in the marketplace where the product is sold?
